GBC Blog

Only a Tenth of the Human Genome is Studied

The Economist / Science and Technology, Sep 20th 2018 ONE tale of Nasreddin, a self-satirising 13th-century philosopher, tells of the time he lost a precious ring. When his wife asks why he is searching in the yard rather than inside, where the ring was lost, Nasreddin explains that the light is better outside. Looking for…

Read More

Discovering the Ancient Origin of Cystic Fibrosis, The Most Common Genetic Disease in Caucasians

https://theconversation.com/discovering-the-ancient-origin-of-cystic-fibrosis-the-most-common-genetic-disease-in-caucasians-100499 Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF), results in tracing it to a group of distinct but mysterious Europeans who lived about 5,000 years ago. CF is the most common, potentially lethal, inherited disease among Caucasians – about…

Read More

The New Era of Medicine (www.innovation.org)

WELCOME TO THE NEW ERA OF MEDICINE Finding lifesaving treatments is our life’s work—the work of the 140,000 biopharmaceutical researchers who boldly leap into the unknown to pioneer tomorrow’s breakthrough cures. It’s also the work of millions of patients who fight against whatever obstacles they face. http://innovation.org/ http://innovation.org/latest-articles

Read More

Seattle’s INDI Acquired by Lung Cancer Tech Company Biodesix

Seattle’s Integrated Diagnostics Acquired by Lung Cancer Technology Company Biodesix Colorado-based Biodesix, a company that creates technology around lung cancer, announced that it has acquired Seattle’s Integrated Diagnostics for an undisclosed sum. Integrated Diagnostics, also known as Indi, develops a test that can rule out patients who do not have lung cancer using a simple…

Read More

Fighting Antimicrobial Resistance with Fast Molecular Diagnostics

Clara Rodríguez Fernández on 3-July-2018 Antimicrobial resistance is predicted to kill more people than cancer by 2050. Is it possible to prevent it? At our Refresh Meetup in Berlin, I talked with Achim Plum, CBO of the diagnostics company Curetis, about what are our best bets to turn the tables in the fight against the threat…

Read More

HHS Delays Common Rule for Another Six Months

HHS Delays Common Rule for Another Six Months June 19, 2018 Delays are becoming commonplace when it comes to the Common Rule. The U.S. Department of Health and Human Services (HHS) just announced it is delaying, again, rollout of the revised Common Rule on the protection of human subjects in clinical trials for six months—until…

Read More

Next-Gen Sequencing (NGS) Finds Further Clinical Utility in Oncology

One of the plenary sessions at the 2017 meeting of the Association for Molecular Pathology—“High Impact Molecular Diagnostics for Cancer and Inherited Diseases”—was a virtual mini-course in the latest and most useful applications of next-generation sequencing to detect germline and somatic mutations in cancer. Both speakers zeroed in on the clinical utility of their innovative…

Read More

China Races Ahead in Gene-Editing Trials

China, Unhampered by Rules, Races Ahead in Gene-Editing Trials U.S. scientists helped devise the Crispr biotechnology tool. First to test it in humans are Chinese doctors HANGZHOU, China—In a hospital west of Shanghai, Wu Shixiu since March has been trying to treat cancer patients using a promising new gene-editing tool. U.S. scientists helped devise the…

Read More

Federal Policy for the Protection of Human Subjects – Updated “Common Rule”

The U.S. Department of Health and Human Services and 15 other federal departments and agencies have announced an Interim Final Rule (IFR) that delays by six months the effective date and general compliance date of the revisions to the “Federal Policy for the Protection of Human Subjects” (also known as the Common Rule) originally published…

Read More

How a New Test Could Solve a Costly Problem

A molecular diagnostics company wants to expand its new cartridge-based platform to help orthopedic surgeons make more informed care decisions for patients with a potential joint infection. Curetis is currently expecting an FDA decision on its new cartridge-based diagnostic platform, the Unyvero system, for lower respiratory infections. The company is also collecting samples to pursue…

Read More